Skip to main content

Advertisement

SpringerLink
Log in

Mantle cell lymphoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Mantle cell lymphoma is an aggressive non-Hodgkin’s lymphoma that remains incurable with current chemotherapeutic approaches. Despite response rates to many regimens of 50% to 70%, the disease typically progresses after chemotherapy with a median survival time of approximately 3 years. There is no clear standard approach for treating mantle cell lymphoma, making it critical that appropriate patients be enrolled in clinical trials. Off protocol, chemotherapy with chlorambucil, CVP (cyclophosphamide, vincristine, and prednisone), or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) can be used in patients who are not candidates for aggressive therapy. Intensive combination chemotherapy regimens have high response rates and may prolong time to progressive disease. High-dose therapy with autologous stem cell transplantation may, but does not appear to, provide longer time to progression, although it may improve survival. For young patients with matched donors, allogeneic transplant is promising in the limited numbers of patients treated. Other agents, including rituximab, fludarabine, and cladribine, have demonstrated activity, but these agents do not appear to offer survival advantages over combination chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Swerdlow SH, Berger F, Isaacson PI, Muller-Hermelink HK: Mantle cell lymphoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Harris NL, Jaffe ES, Stein H, Vardiman JW. Lyon: IARC Press; 2001:168. Current pathologic criteria for diagnosis of MCL with discussion of histologic variants, biology, and clinical features.

    Google Scholar 

  2. Swerdlow SH, Williams ME: From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of three decades. Hum Pathol 2002, 33:7–20.

    Article  PubMed  CAS  Google Scholar 

  3. Romaguera JE, Medeiros LJ, Hagemeister FB, et al.: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586–591.

    Article  PubMed  Google Scholar 

  4. Weisenburger DD, Vose JM, Greiner TC, et al.: Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000, 64:190–196. A retrospective review of pathologic and clinical features and their prognostic significance.

    Article  PubMed  CAS  Google Scholar 

  5. Campo E, Raffeld M, Jaffe ES: Mantle-cell lymphoma. Semin Hematol 1999, 36:115–127.

    PubMed  CAS  Google Scholar 

  6. Samaha H, Dumontet C, Ketterer N, et al.: Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281–1287.

    Article  PubMed  CAS  Google Scholar 

  7. Meusers P, Engelhard M, Bartels H, et al.: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365–380.

    Article  PubMed  CAS  Google Scholar 

  8. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al.: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819–2826.

    PubMed  CAS  Google Scholar 

  9. Khouri IF, Romaguera J, Kantarjian H, et al.: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803–3809.

    PubMed  CAS  Google Scholar 

  10. Romaguera J, Cabanillas F, Dang NH, et al.: Mantle cell lymphoma: update on results after R-HCVAD without stem cell transplantation [abstract]. Ann Oncol 2002, 13:8. An update of a prior publication demonstrating the activity of this regimen without stem cell transplant.

    Article  Google Scholar 

  11. Foran JM, Rohatiner AZ, Cunningham D, et al.: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small Bcell lymphocytic lymphoma. J Clin Oncol 2000, 18:317–324.

    PubMed  CAS  Google Scholar 

  12. Howard OM, Gribben JG, Neuberg DS, et al.: Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288–1294.

    Article  PubMed  CAS  Google Scholar 

  13. Zinzani PL, Magagnoli M, Moretti L, et al.: Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle cell lymphoma. J Clin Oncol 2000, 18:773–779.

    PubMed  CAS  Google Scholar 

  14. Rummel MJ, Chow KU, Karakas T, et al.: Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin’s lymphoma. Eur J Cancer 2002, 38:1739–1746.

    Article  PubMed  CAS  Google Scholar 

  15. Vose JM, Bierman PJ, Weisenburger DD, et al.: Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000, 6:640–645. A retrospective review of 40 patients treated with autologous stem cell transplantation, with discussion of outcome and prognostic features.

    Article  PubMed  CAS  Google Scholar 

  16. Gopal AK, Rajendran JG, Petersdorf SH, et al.: Highdose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158–3162.

    Article  PubMed  CAS  Google Scholar 

  17. Khouri IF, Saliba R, Hosing C, et al.: Long-term followup of autologous stem cell transplantation in first remission in patients with diffuse mantle cell lymphoma [abstract]. Ann Oncol 2002, 13:78.

    Google Scholar 

  18. Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310–4316.

    Article  PubMed  CAS  Google Scholar 

  19. Lin TS, Howard OM, Neuberg DS, et al.: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 2002, 43:793–797.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, University of Virginia Health System, Box 800716, 22908, Charlottesville, VA, USA

    John J. Densmore MD, PhD

Authors
  1. John J. Densmore MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael E. Williams MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Densmore, J.J., Williams, M.E. Mantle cell lymphoma. Curr. Treat. Options in Oncol. 4, 281–287 (2003). https://doi.org/10.1007/s11864-003-0003-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0003-1

Keywords

Search

Navigation